The hallmarks of restless legs syndrome (RLS) are a desire to move the limbs due to sensory discomfort, motor restlessness, and worsening of symptoms during rest or at night. 1 Sensory symptoms cause the greatest discomfort, 2 and are commonly localized to muscle.
Sensory and motor symptoms can be improved with dopaminergic medications, some anticonvulsants, opioids, and to a lesser extent with GABAactive hypnotics. Botulinum toxin has been suggested as a potential therapy for refractory RLS, based on its ability to reduce peripheral and central sensitization to pain. 3 In an unblinded observational study by Rotenberg and colleagues, IM injections of 70 -320 mouse units (mU) of botulinum toxin type A (BTX-A; Botox, Irvine, CA) were injected into the legs of three patients with RLS and demonstrated symptom improvement, reduced medication use, and a reduction in daytime sleepiness. 4 Based on these findings, we conducted a randomized, placebocontrolled, double-blind, crossover study.
Methods. Patients. We enrolled six patients from June to
July 2007 who were age 18 or older, had a diagnosis of primary RLS based on International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria, 1 had a minimum score of 11 (at least moderate severity) on the IRLSSG rating scale (IRLS), 5 and were stable on medications for greater than 6 weeks prior to enrollment. Patients were excluded for an abnormal neurologic examination, abnormal laboratory test results, a dermatologic disorder precluding leg injections, pregnancy/lactation, incapacity for informed consent, taking medications which could interact with BTX-A, or on anticoagulants. This study was approved by the National Institute of Neurological Disorders and Stroke Institutional Review Board and all patients provided written informed consent.
Study design. Patient assessment included a medical history, neurologic examination, and baseline ratings. Eligible patients were evaluated by a second investigator who documented symptom location. A standard set of muscles were selected as potential targets: quadriceps femoris (QF), tibialis anterior (TA), gastrocnemius (GCS), and soleus (SOL). Injections were conducted under needle-EMG guidance. After baseline ratings, patients were randomized to receive BTX-A or saline. Each 100 mU vial was reconstituted with 2 mL of preservative-free normal saline (5 mU/0.1 mL). The maximum dose was 90 mU per leg, distributed in the following sites (number of injections): QF-40mU (4); TA-20mU (2); GCS-20mU (2); SOL-10mU (1). At week 12, patients received the alternate compound with continued monitoring.
We used the IRLS and the Clinical Global Improvement scale (CGI) to assess efficacy. To monitor adverse effects (AE), patients were asked to rate from 0 (no symptoms) to 10 (severe symptoms) the presence of weakness, pain, swelling, and redness based on the preceding 2 weeks. Ratings were completed at baseline (weeks 0 and 12), and 2 and 4 weeks postinjections.
The primary outcome measure was mean change in IRLS from baseline at 4 weeks postinjection. Secondary outcomes included mean IRLS change from baseline at 2 weeks postinjection, mean CGI scores at weeks 2 and 4, and reported AEs. We performed a power analysis using standard treatment and placebo response rates reported for pramipexole. 6 We estimated a mean difference from baseline between placebo and BTX-A of 10 points Ϯ 3 (SD) on the IRLS. We therefore required a sample size of 3 patients per group (power ϭ 0.80, ␣ ϭ 0.05).
Results. Seven patients were screened, with one excluded due to leukocytosis on laboratory testing. All remaining patients completed the study. Five patients were on stable doses of a dopamine agonist, and one patient was on a stable dose of clonazepam. No patient had received prior BTX treatment. Group demographics were as follows: 57.7 Ϯ 8.8 years of age, equal male-female ratio, 33.5 Ϯ 14.4 years disease duration, and an IRLS score of 27 Ϯ 4.8. All patients received the maximum BTX dose of 90 mU/leg with the exception of one patient who had no symptoms in the proximal legs and did not receive injections into his QF. At week 2, placebotreated patients noted a 5.0 Ϯ 5.1 point improvement on the IRLS vs a 1.0 Ϯ 3.5 point improvement in the BTX-arm (p ϭ 0.06). At week 4, placebotreated patients maintained only a 2.7 Ϯ 5.9 point improvement from baseline, whereas BTX-treated patients showed a 5.0 Ϯ 6.0 point improvement (p ϭ 0.24). The CGI showed similar findings for the BTX-arm with scores of 4.3 Ϯ 0.8 at week 2 (p ϭ 0.01) and 3.7 Ϯ 1.4 at week 4 (p ϭ 0.74), compared to placebo-arm scores of 2.8 Ϯ 1.2 at week 2 and 3.8 Ϯ 1.7 at week 4. We compared baseline scores at week 0 and week 12 to assess for any carryover effect in the BTX-arm and found no differences (p ϭ 0.55). Reported AEs were similar between groups, with mean placebo AE scores of 1.5 Ϯ 2.5 at baseline, 3.2 Ϯ 5.4 at week 2, and 5 Ϯ 7.4 at week 4, while BTX-A scores were 1.8 Ϯ 3.3 at baseline, 6.3 Ϯ 7.1 at week 2, and 4.5 Ϯ 5.6 at week 4. Two patients reported mild weakness following both placebo and BTX-A injections.
Discussion. This study showed no significant improvement in IRLS and CGI at week 4 for BTX-A. A statistically significant benefit was noted on the CGI secondary endpoint for the placebo group at week 2. AEs were similar between the groups. Any future studies should be powered to account for the significant placebo response while exploring higher doses without unmasking controls. 
FINE-MAPPING THE GENE FOR X-LINKED MYOPATHY WITH EXCESSIVE AUTOPHAGY
Myopathies with autophagic vacuoles with sarcolemmal features (MAVSF) are a group of skeletal muscle diseases exhibiting autophagic vacuolation of myofibers. The vacuoles have membranes of mixed sarcolemmal, lysosomal, and autophagosomal origin. They contain partially degraded cell components including proteins, glycogen, membrane whorls, and organelles. 1 The two most common MAVSF are Danon disease and X-linked myopathy with excessive autophagy (XMEA). Danon disease is caused by mutations in the LAMP2B isoform of the lysosome-associated membrane protein-2 (LAMP2) gene. 2 LAMP2B may play a role in approaching lysosomes to merge with autophagosomes. 1 The genes for XMEA and the other MAVSF are unknown. We previously mapped the XMEA gene to chromosomal band Xq28, one of the most gene-rich regions of the genome, in a 4.64 Mb locus containing over 110 genes. 3 We now refine this locus to 0.58 Mb containing only six genes. XMEA is inherited recessively, affecting boys and sparing carrier females. Onset is between ages 6 and 18 years with weakness and gradual wasting of the proximal muscles of the lower extremities. Other skeletal muscle groups are progressively affected in-cluding the upper limb girdle and distal muscles. Patients are wheelchair-bound in their 50s, and lifespan appears to be shortened due to respiratory muscle involvement. Considerable variation from this clinical picture can be seen, with some patients exhibiting extremely mild and sometimes no weakness or wasting (see below). The central and peripheral nervous systems, the heart, and other organs are clinically unaffected. Pathologically, the myofibers exhibit several highly unusual features. The vacuoles they contain migrate to the myofiber surface and extrude their contents extracellularly forming a field of cell debris around the fiber. The myofiber basal lamina is reduplicated multifold. Major Histocompatibility Class I (MHC-I) antigens are expressed, yet there is no inflammation. Membrane attack complexes are deposited around the fiber, possibly on the profuse membranous and other cell debris extruded by vacuoles. 4, 5 Electromyographic (EMG) findings are also unusual. Patients with XMEA have no clinical myotonia, yet EMG reveals florid complex repetitive and myotonic discharges in all muscle groups, including clinically unaffected muscles such as facial and bulbar muscles. The EMG abnormality is the most constant feature of the disease: in some families the clinical phenotype (muscle weakness and wasting) is non- penetrant, i.e., some males carrying the Xq28 disease-associated haplotype do not have weakness and wasting, but these individuals still harbor the characteristic EMG phenotype. 6, 7 We previously reported a large American XMEA family with 12 affected male members. Affected males in this family, including two individuals with the EMG-only phenotype, share a common Xq28 haplotype (long rectangle in the figure, A) , which is not present in males who are clinically and electromyographically unaffected. 7 We now have recruited a new branch of the family (individual R and her descendants in the figure, A). Genotyping revealed that the X chromosome inherited by R from her mother is a recombinant of the mother's two X chromosomes and contains part of the disease-associated haplotype (short rectangle in the figure, A). Two of R's sons inherited this recombinant chromosome ( figure, A) . Neurologic examination and EMG in these two men are normal, indicating that they do not have the XMEA mutation. The XMEA gene is therefore not in the part of the disease haplotype they inherited and is thus outside the region of the short rectangle. The gene is therefore centromeric to microsatellite marker BV106355, and this marker is the new telomeric border of the XMEA locus ( figure, A) . On the centromeric side, the new boundary is the single nucleotide polymorphism marker RS1149374 (figure, B) . This was determined by genotyping two previously described 3, 5 and distantly related French families in whom we found a common disease haplotype extending from the end of the chromosome until RS1149374 (figure, B) . In summary, the refined XMEA locus is the 0.58 Mb between RS1149374 and BV106355 (figure, C).
Our work eliminates 87% of genomic sequence and 95% of genes from the previously defined XMEA locus. The six genes in the refined locus are LOC286456, LOC203547, FATE1, PASD1, PRRG3, and CNGA2. LOC286456 and LOC203547 are novel uncharacterized genes containing no known motifs. FATE1 and PASD1 are expressed exclusively in testis, which makes them poor candidates. PRRG3 encodes a protein with a high-affinity calcium binding site, while CNGA2 encodes a cyclic nucleotide-gated cation channel. Either gene may underlie the myofiber membrane electrical instability that is such a constant feature in XMEA. The XMEA gene, whichever of the six it is, will be a new entry point, following LAMP2, into understanding autophagic vacuolation of skeletal muscle. 
